seniprutug

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
seniprutug

GtoPdb Ligand ID: 13939

Synonyms: BCD-180 | BCD180

seniprutug is an approved drug

Compound class: Antibody

Comment: Seniprutug (BCD-180) is a monoclonal antibody that targets T cell receptor beta variable 9 (TRBV9) [1]. It induces antibody-dependent cellular cytotoxicity in the target effector T cell population without causing risk of systemic immunosuppression (that would be caused by destroying T cell subsets that are responsible for essential protective functions).

References
1. Britanova OV, Lupyr KR, Staroverov DB, Shagina IA, Aleksandrov AA, Ustyugov YY, Somov DV, Klimenko A, Shostak NA, Zvyagin IV et al.. (2023) Targeted depletion of TRBV9⁺ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med, 29 (11): 2731-2736. [PMID:37872223]
2. Castro-Santos P, Díaz-Peña R. (2024) Precision immunotherapy: TRBV9+ T-cell depletion in ankylosing spondylitis. Rheumatology (Oxford), 63 (9): e251-e252. [PMID:38305452]
3. Nasonov EL, Mazurov VI, Lila AM, Dubinina TV, Gaidukova IZ, Lapshina SA, Klimenko AA, Somov DV, Lukyanov SA, Chudakov DM et al.. (2025) The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA. Dokl Biochem Biophys, [Epub ahead of print]. [PMID:40353961]

References

1. Britanova OV, Lupyr KR, Staroverov DB, Shagina IA, Aleksandrov AA, Ustyugov YY, Somov DV, Klimenko A, Shostak NA, Zvyagin IV et al.. (2023)
Targeted depletion of TRBV9⁺ T cells as immunotherapy in a patient with ankylosing spondylitis.
Nat Med, 29 (11): 2731-2736. [PMID:37872223]

2. Castro-Santos P, Díaz-Peña R. (2024)
Precision immunotherapy: TRBV9+ T-cell depletion in ankylosing spondylitis.
Rheumatology (Oxford), 63 (9): e251-e252. [PMID:38305452]

3. Nasonov EL, Mazurov VI, Lila AM, Dubinina TV, Gaidukova IZ, Lapshina SA, Klimenko AA, Somov DV, Lukyanov SA, Chudakov DM et al.. (2025)
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA.
Dokl Biochem Biophys, [Epub ahead of print]. [PMID:40353961]